HR-6009-119
Referred to the Committee on Armed Services, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Chrissy Houlahan (D-PA)
What it does
This bill would require the Secretary of Defense, within one year, to submit a strategy to Congress on the national security implications of emerging biotechnology. The strategy must address biomanufacturing facilities, military specifications, procurement agreements, wargaming exercises, research challenges, a biotechnology regulatory science program, and NATO coordination on biotechnology purchasing and research.
Who benefits
Biotechnology companies and contractors seeking defense-related manufacturing contracts or advance market commitments, Department of Defense research and acquisition offices, NATO allies seeking coordinated biotechnology procurement, and defense planners seeking to integrate biotechnology into military strategy.
Who is hurt
No group bears a direct material burden, though taxpayers fund the strategy's development and any resulting programs, and traditional suppliers of non-biotechnology defense materials could face longer-term competitive pressure if the Department shifts specifications toward biotechnology-based products.
Supporters argue
Supporters argue that biotechnology is a rapidly advancing field with major implications for military materials, medical countermeasures, and supply chain resilience, and that the Department of Defense currently lacks a coordinated strategy to address it. They contend that requiring this strategy, including provisions for advance market commitments and NATO coordination, would help the United States and its allies stay ahead of competitors who are investing heavily in biotechnology for strategic advantage.
Opponents argue
Opponents argue that mandating another Pentagon strategy document adds bureaucratic reporting requirements without guaranteeing meaningful follow-through, noting that similar strategy mandates have sometimes produced reports that are late, vague, or shelved without action. They contend that provisions like advance market commitments and offtake agreements could commit the government to future spending or favor specific companies before Congress has had a chance to evaluate the underlying policy.
Constitutional context
This bill directs an executive department to produce a report to Congress and raises no constitutional question beyond Congress's Article I authority to organize the armed forces and oversee defense spending, since it does not authorize military action or restrict individual rights.
Checks and balances
Congress directs the Department of Defense to produce a strategy and report back, preserving legislative oversight, while the Executive Branch retains discretion over the strategy's substantive content and implementation.
Historical precedent
Congress has frequently required Department of Defense strategy reports on emerging technology areas, such as prior mandates for artificial intelligence and hypersonics strategies, though no single bill is a direct precedent for biotechnology specifically.